Headquartered in Hampton, NJ·Fiscal year ends December·NASDAQ: CLDX·celldex.com
About Celldex Therapeutics
Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for allergic, inflammatory and autoimmune disorders, with a focus on mast cell biology.
Its lead candidate, barzolvolimab (CDX-0159), is a first-in-class humanized monoclonal antibody. It binds a unique part of the KIT receptor to inhibit mast cell activity and survival. The drug has completed Phase 3 topline readouts (EMBARQ-CSU1 and -CSU2) in chronic spontaneous urticaria, and the company plans a BLA submission in 2027. Barzolvolimab is also in a Phase 3 study (EMBARQ-ColdU and -SD) in cold urticaria and symptomatic dermographism, and in a Phase 2 study in atopic dermatitis.
Celldex also runs a bispecific antibody platform anchored on neutralizing soluble stem cell factor (SCF). Its first candidate, CDX-622, targets both SCF and TSLP and is in a Phase 1 proof-of-mechanism study in asthma, with planned expansion into allergic rhinitis and food allergy.
The company currently generates no material revenue; historical revenue came from contracts, grants and services, including work with Rockefeller University. It funds operations from its cash and marketable securities and is building commercial capabilities ahead of a potential barzolvolimab launch. Updated
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
Jefferies has compiled a list of over 30 biotech events taking place in 2018 that could result in significant stock moves. Some stocks have the potential to double or even crater, should…
The top analyst upgrades, downgrades and other research calls include American Airlines, Boeing, Cabot Oil & Gas, Pandora Media, Southern Co. and Vertex Pharmaceuticals.
Celldex Therapeutics was another big mover coming out of the Annual Meeting for the American Society of Clinical Oncology (ASCO). Unfortunately, the move was to the downside.
Celldex Therapeutics is a clinical-stage biotechnology company developing antibody-based therapies for allergic, inflammatory and autoimmune disorders, with a focus on mast cell biology. Its lead candidate, barzolvolimab (CDX-0159), is a first-in-class humanized monoclonal antibody.
What is the CLDX stock price target?
The Wall Street consensus 12-month price target for CLDX is $64.00.